ArticleCureus2026
Acute Disseminated Encephalomyelitis Following Nivolumab Therapy for Hodgkin Lymphoma: A Case Report and Literature Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of immune checkpoint inhibitors (ICIs) such as nivolumab, a programmed death receptor-1 (PD-1) inhibitor, has transformed the management of numerous malignancies. However, they are associated with multiple immune-related adverse events (irAEs), including central nervous system (CNS) demyelination such as acute disseminated encephalomyelitis (ADEM). We report a case of ADEM following nivolumab monotherapy and review the literature on similar presentations. We present the case of a patient with Hodgkin lymphoma who presented with confusion, disorientation, and seizures following nivolumab therapy. Serial magnetic resonance imaging (MRI) revealed the development of multifocal white matter lesions suggestive of demyelination. The clinical picture, coupled with extensive investigations, led to a diagnosis of ADEM. The patient was managed with intravenous (IV) methylprednisolone, IV immunoglobulin (IVIG), and plasmapheresis and showed clinical improvement. A review of the literature yielded only a few examples of nivolumab monotherapy-induced autoimmune encephalitis and ADEM. The overlap in the clinical presentations of those neurological adverse events could make the diagnosis more challenging. ICIs are associated with several CNS irAEs, such as ADEM. This case highlights the need for high clinical vigilance for ADEM, an ICI-related CNS complication. Serial imaging and exclusion of alternative etiologies are essential for timely diagnosis and management. Patient outcomes may be improved by early detection and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.